

**GlaxoSmithKline Pharmaceuticals Limited**

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

**UNAUDITED FINANCIAL RESULTS  
FOR THE QUARTER AND NINE MONTHS ENDED 30TH SEPTEMBER, 2007**

Unaudited			Unaudited		(Rs. lakhs)
3 months ended 30.09.2007	3 months ended 30.09.2006		9 months ended 30.09.2007	9 months ended 30.09.2006	Audited Year ended 31.12.2006
45709	43279	Sales	134499	132868	167757
3629	3364	Less: Excise Duty on Sales	10712	9603	12465
42080	39915	Net Sales	123787	123265	155292
2009	1610	Other Income	5785	4171	6158
1376	926	Interest Income (net)	3441	2419	3426
45465	42451	Total Income	133013	129855	164876
		Expenditure			
2485	(583)	(Increase) / decrease in stock-in-trade and work in progress	3980	968	(1253)
7028	7933	Consumption of raw and packing materials	23675	21952	29700
7290	8554	Purchase of traded goods	21567	27420	34005
16803	15904	Total materials consumed	49222	50340	62452
153	212	Excise duty on samples and (increase) / decrease in stock-in-trade	680	612	1450
4006	3838	Employees cost	12244	11841	15367
376	407	Depreciation	1114	1174	1585
7610	7372	Other expenditure	21807	21751	29428
(156)	(238)	Recovery of expenses	(565)	(735)	(1001)
28792	27495	Total	84502	84983	109281
16673	14956	Profit before Tax and Exceptional Items	48511	44872	55595
		Tax Expense			
5547	4985	Current tax (including fringe benefits tax)	16195	15409	18890
216	64	Deferred tax	631	107	533
5763	5049	Total	16826	15516	19423
10910	9907	Net Profit after Tax before Exceptional Items	31685	29356	36172
13991	18636	Exceptional Items (net of tax)	13991	18416	18379
24901	28543	Net Profit	45676	47772	54551
8470	8470	Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470	8470
		Reserves excluding Revaluation Reserves			111001
		Earnings Per Share (EPS)			
12.9	11.7	Basic and diluted EPS before exceptional items (Rs.)	37.4	34.7	42.7
29.4	33.7	Basic and diluted EPS after exceptional items (Rs.)	53.9	56.4	64.4
		Public Shareholding			
41785529	41785529	Number of shares	41785529	41785529	41785529
49.3%	49.3%	Percentage of shareholding	49.3%	49.3%	49.3%

- The growth in Sales (excluding the Animal Health business which was divested last year) was 8.4% and in Profit before Tax and Exceptional Items was 13.0% for the quarter ended 30th September 2007 on a comparable basis. The growth was primarily driven by focus products which registered a double digit growth. The figures for the current period are not comparable with those of the previous period in view of the sale of the Animal Health business on 31st July, 2006.
- The Company has, with effect from 1st January, 2007, adopted Accounting Standard 15, Employee Benefits (revised 2005), issued by the Institute of Chartered Accountants of India. Consequently, the additional liability for employee benefits based on actuarial valuation as at 1st January, 2007, amounting to Rs. 1470.05 lakhs (net of deferred tax credit of Rs. 745.88 lakhs), has been adjusted against General Reserve as at 1st January, 2007 and an additional estimated charge of Rs. 150 lakhs has been debited to Employees cost for the nine months ended 30th September, 2007.
- The Board of Directors, at its meeting held on 26th July, 2007, approved the proposal for sale of the Fine Chemicals business as a going concern to Thermo Electron LLS India Private Limited for a total consideration of Rs. 240 crores. Shareholders of the Company approved the proposal by postal ballot on 19th September, 2007. The sale has been completed effective from the close of business hours of 30th September, 2007. Exceptional Items (net of tax) of Rs.140 crores for the quarter and nine months ended 30th September, 2007 represent profit on such sale (net of provision for completion covenants, expenses incidental to sale and current tax thereon). Fine Chemicals business forms part of the Company's 'Other Businesses' segment.
- In addition to the launch of Arixtra (Fondaparinux), a new generation anti-coagulant, in the second quarter of this year, the Company has launched Carzec (Carvedilol) in the third quarter. Carzec is a drug of choice in congestive cardiac failure and its launch marks the Company's entry into the growing cardiovascular market and also complements the Company's diabetes portfolio.
- There was 1 investor complaint pending as at the beginning of the quarter. The Company has received 7 complaints from the investors during the quarter and all of them have since been resolved, leaving no investor complaints unresolved at the end of the quarter.
- The above Results were reviewed by the Audit Committee and were approved by the Board of Directors at their meetings held on 25th October, 2007. The statutory auditors have carried out a limited review of the results for the quarter and nine months ended 30th September, 2007.

By Order of the Board

Dr. Hasit B. Joshipura  
Managing Director

25th October, 2007